Evaluation of Superior Mesenteric Artery Diameter and Flow in Aneurysmal Subarachnoid Hemorrhage Patients Undergoing Hypertensive Therapy for Cerebral Artery Vasospasm
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Florida
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Change between baseline and 21 days of abdominal ultrasound measurement of the doppler flow velocity in the superior mesenteric artery
Study Overview
Brief Summary
The purpose of this research study is to determine if the diameter and flow of the superior mesenteric artery in patients with aneurysmal subarachnoid hemorrhage undergoing hypertensive therapy for cerebral artery vasospasm are effected enough to justify withholding enteral nutrition.
Detailed Description
Study measurements of the diameter and Doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) in patients undergoing hypertensive therapy for cerebral vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH), to justify the withholding of enteral nutrition.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 99 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient diagnosed with aSAH
Exclusion Criteria
- •Hemodynamic instability
- •Already receiving vasopressor therapy
- •Non-aneurysmal SAH
- •Intracranial hemorrhage of other cause
- •Not anticipated to receive hypertensive therapy with vasoactive medications for cerebral vasospasm from SAH or suspected aSAH
- •Unable to visualize SMA using ultrasound
- •Pregnancy
Outcomes
Primary Outcomes
Change between baseline and 21 days of abdominal ultrasound measurement of the doppler flow velocity in the superior mesenteric artery
Time Frame: Change from baseline up to 21 days
Change between baseline and 21 days of abdominal ultrasound measurement of the diameter in the superior mesenteric artery
Time Frame: Change from baseline up to 21 days
Secondary Outcomes
- Number of participants with non-occlusive mesenteric ischemia (NOMI)(Change from baseline up to 21 days)
- Number of participants with non occlusive bowel necrosis (NOBN)(Change from baseline up to 21 days)